Oramed Pharmaceuticals Inc
ORMP
查看详细走势图
2.927USD
-0.003-0.10%
交易中 （美东）报价延迟15分钟
119.53M总市值
2.79市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.10%
5天
-4.66%
1月
+13.45%
6月
+37.42%
今年开始到现在
+20.95%
1年
+23.50%
查看详细走势图
TradingKey Oramed Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Oramed Pharmaceuticals Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名167/404位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价3.25。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Oramed Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
3.250
目标均价
+36.55%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Oramed Pharmaceuticals Inc亮点
亮点风险
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
业绩转亏
公司业绩转亏，最新年度亏损美元
估值合理
公司最新PE估值2.79，处于3年历史合理位
机构减仓
最新机构持股7.28M股，环比减少14.63%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值148.90K
Oramed Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Oramed Pharmaceuticals Inc简介
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
公司代码ORMP
公司Oramed Pharmaceuticals Inc
CEOKidron (Nadav)
网址https://oramed.com/
常见问题
Oramed Pharmaceuticals Inc(ORMP)的当前股价是多少？
Oramed Pharmaceuticals Inc(ORMP)的当前股价是 2.927。
Oramed Pharmaceuticals Inc的股票代码是什么？
Oramed Pharmaceuticals Inc的股票代码是ORMP。
Oramed Pharmaceuticals Inc股票的52周最高点是多少？
Oramed Pharmaceuticals Inc股票的52周最高点是3.200。
Oramed Pharmaceuticals Inc股票的52周最低点是多少？
Oramed Pharmaceuticals Inc股票的52周最低点是1.820。
Oramed Pharmaceuticals Inc的市值是多少？
Oramed Pharmaceuticals Inc的市值是119.53M。
Oramed Pharmaceuticals Inc的净利润是多少？
Oramed Pharmaceuticals Inc的净利润为-19.06M。
现在Oramed Pharmaceuticals Inc(ORMP)的股票是买入、持有还是卖出？
根据分析师评级，Oramed Pharmaceuticals Inc(ORMP)的总体评级为--，目标价格为3.250。
Oramed Pharmaceuticals Inc(ORMP)股票的每股收益（EPS TTM）是多少
Oramed Pharmaceuticals Inc(ORMP)股票的每股收益（EPS TTM）是1.050。
相关品种
